Immunoproteasome is an intracellular protease, whose pivotal role is degradation of abnormally folded and damaged proteins. Inhibition of the proteolytic activity of the immunoproteasome could be advantageous in the treatment of certain cancers and autoimmune diseases. The selected immunoproteasome inhibitors did not show the intended effect on the cell line, which may be due to the insufficient intracellular inhibitor concentration. The selected inhibitors are very lipophilic and because they are covalent inhibitors, they can also react with proteins in the cell medium. In the master's thesis we will try to develop a method based on UHPLC to determine the intracellular concentration of selected inhibitors.
|
